What are the approved indications for Vraylar (cariprazine) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vraylar (Cariprazine) FDA-Approved Indications

Vraylar (cariprazine) is FDA-approved for four distinct indications in adults: schizophrenia, acute manic or mixed episodes of bipolar I disorder, bipolar I depression, and as adjunctive therapy to antidepressants for major depressive disorder (MDD). 1

Complete List of FDA-Approved Indications

Adult Indications

  • Schizophrenia - Treatment in adults
  • Bipolar I Disorder - Acute Mania/Mixed Episodes - Acute treatment in adults
  • Bipolar I Depression - Treatment of depressive episodes in adults
  • Major Depressive Disorder (MDD) - Adjunctive therapy to antidepressants in adults

Pediatric Indications

  • Schizophrenia - Treatment in patients ≥13 years of age
  • Bipolar I Disorder - Acute Mania/Mixed Episodes - Acute treatment in patients ≥10 years of age

1

Key Distinguishing Features

Vraylar is unique among atypical antipsychotics as the only agent with FDA approval for all four major adult indications (schizophrenia, bipolar mania, bipolar depression, and adjunctive treatment of MDD). This broad approval reflects its dopamine D3-preferring D3/D2 receptor partial agonist mechanism, which provides 10-fold higher affinity for D3 versus D2 receptors. 1, 2

Dosing by Indication

The recommended dosing varies significantly by indication:

  • Schizophrenia (adults): 1.5-6 mg daily (start 1.5 mg)
  • Schizophrenia (pediatric 13-17 years): 1.5-4.5 mg daily (start 0.5 mg)
  • Bipolar mania (adults): 3-6 mg daily (start 1.5 mg)
  • Bipolar mania (pediatric 10-17 years): 3-4.5 mg daily (start 0.5 mg)
  • Bipolar depression (adults): 1.5-3 mg daily (start 1.5 mg; maximum 3 mg)
  • Adjunctive MDD (adults): 1.5-3 mg daily (start 1.5 mg; maximum 3 mg)

1

Critical Safety Considerations

Vraylar carries two boxed warnings: increased mortality in elderly patients with dementia-related psychosis (not an approved indication), and increased risk of suicidal thoughts/behaviors in pediatric and young adult patients treated with antidepressants. 1

The medication has a notably long half-life due to its active metabolite didesmethyl-cariprazine (1-3 weeks), requiring monitoring for adverse reactions for several weeks after initiation or dose changes. 1

References

Related Questions

Does Vraylar (cariprazine) cause nightmares?
Is it safe to combine Vraylar (cariprazine) with Prozac (fluoxetine), and what dosing adjustments or monitoring are required?
Can an SNRI be safely combined with Vraylar (cariprazine), and what dosing and monitoring considerations are recommended?
Is it safe to combine buspirone (Buspar) with cariprazine (Vraylar), and how should it be dosed and monitored?
Can Vraylar (cariprazine) be used during the first trimester of pregnancy?
Can hydroxyzine cause light‑headedness and orthostatic hypotension, and how should these side effects be managed?
What adjustments to my insulin regimen (Toujeo [insulin glargine] 65 units daily and Novolog [insulin aspart] 20 units three times daily) are recommended for persistent blood glucose levels around 300 mg/dL?
Can a fracture of the L4 vertebra cause increased left hip pain?
Are fetal rhabdomyomas typically identified on prenatal ultrasound during the second trimester or the third trimester of pregnancy?
Which cardio‑selective β1‑blocker is recommended for a patient with postural orthostatic tachycardia syndrome (POTS) and asthma?
What is the recommended starting dose of bisoprolol for a patient with Postural Orthostatic Tachycardia Syndrome (POTS)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.